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WRNIP1 Protects Reversed DNA Replication Forks
from SLX4-Dependent Nucleolytic Cleavage
Bartlomiej Porebski,1,3,* Sebastian Wild,1 Sandra Kummer,1 Sarah Scaglione,2 Pierre-Henri L. Gaillard,2
and Kerstin Gari1,4,*
SUMMARY
During DNA replication stress, stalled replication forks need to be stabilized to prevent fork collapse
and genome instability. The AAA + ATPase WRNIP1 (Werner Helicase Interacting Protein 1) has been
implicated in the protection of stalled replication forks from nucleolytic degradation, but the under-
lying molecular mechanism has remained unclear. Here we show that WRNIP1 exerts its protective
function downstream of fork reversal. Unexpectedly though, WRNIP1 is not part of the well-studied
BRCA2-dependent branch of fork protection but seems to protect the junction point of reversed
replication forks from SLX4-mediated endonucleolytic degradation, possibly by directly binding to
reversed replication forks. This function is specific to the shorter, less abundant, and less conserved
variant of WRNIP1. Overall, our data suggest that in the absence of BRCA2 and WRNIP1 different
DNA substrates are generated at reversed forks but that nascent strand degradation in both cases
depends on the activity of exonucleases and structure-specific endonucleases.
INTRODUCTION
During DNA replication, forks can encounter a plethora of situations that hinder their progression, such as a
shortageof nucleotides, unrepairedDNA lesions, torsional stress, DNA secondary structures, transcription com-
plexes, and RNA:DNA hybrids (Zeman and Cimprich, 2014). In response to virtually all such situations of DNA
replication stress, stalled replication forks seem toget remodeled into four-way junctions (Zellweger et al., 2015),
presumably to stabilize them until the fork-stalling obstacle is cleared (Neelsen and Lopes, 2015). During this
process, termed replication fork reversal, DNA translocases, such as ZRANB3, SMARCAL1, and HLTF, drive
the reannealing of the two parental DNA strands and the concomitant annealing of the newly synthesized
strands to form a four-way junction (Achar et al., 2011, 2015; Be´tous et al., 2012; Ciccia et al., 2012; Kile et al.,
2015; Poole and Cortez, 2017; Vujanovic et al., 2017). In addition to these factors, the well-known recombination
protein RAD51 is required for the formation of reversed forks (Zellweger et al., 2015), a function that is, in contrast
to its role in homologous recombination, independent of its interaction partner BRCA2 (Mijic et al., 2017).
Although replication fork reversal is considered a protective measure, reversed replication forks, when not
adequately stabilized, represent a source of genome instability, because they can become entry points for
uncontrolled exonucleolytic degradation (Kolinjivadi et al., 2017; Lemac¸on et al., 2017; Mijic et al., 2017;
Taglialatela et al., 2017). BRCA2 plays an important role in the protection of reversed replication forks, pre-
sumably by assembling RAD51 filaments on the 30-single-stranded (ss) DNA end of the reversed arm
(Hashimoto et al., 2010; Mijic et al., 2017; Schlacher et al., 2011). A number of other proteins have been
implicated in the protection of stalled replication forks from nucleolytic cleavage, such as BRCA1, FANCD2,
REV1, BOD1L (Higgs et al., 2015; Schlacher et al., 2012; Yang et al., 2015), and more recently WRNIP1
(Leuzzi et al., 2016). Their mode of action in this context has however remained elusive, and it is unclear
whether they exert their protective role at the level of the stalled or the reversed replication fork.
The AAA + ATPase WRNIP1 had initially been implicated in the maintenance of genome stability because
of its physical interactions with DNA replication and repair proteins, such as the eponymous Werner heli-
case (WRN) and DNA polymerase delta (Kawabe et al., 2001; Tsurimoto et al., 2005). Moreover, it was found
to colocalize with the replication fork remodeler ZRANB3 upon PCNA hyperubiquitination (Ciccia et al.,
2012) and identified as a replication-associated repair protein enriched on nascent chromatin upon repli-
cation stress (Alabert et al., 2014; Dungrawala et al., 2015).
Here we provide evidence that, as BRCA2, WRNIP1 protects stalled replication forks that have under-
gone fork reversal. In contrast to BRCA2, however, WRNIP1 does not seem to protect the end of the
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protruded arm, but rather the junction point, of the reversed fork. Our data suggest that WRNIP1 may
be able to do so by directly binding to reversed replication forks, thereby shielding them from SLX4-
mediated cleavage.
RESULTS
WRNIP1 Protects Reversed Replication Forks in aMechanistically DifferentWay Than BRCA2
We first asked whether WRNIP1 was involved in the protection of reversed rather than stalled replication
forks, similarly to what was recently reported for BRCA2 (Kolinjivadi et al., 2017; Lemac¸on et al., 2017; Mijic
et al., 2017; Taglialatela et al., 2017). To do so, we employed a widely used DNA fiber labeling approach in
U2OS cells, in which we gave two consecutive pulses of CldU and IdU followed by a 5-h treatment with hy-
droxyurea to block DNA replication (Figure 1A; Table S1). In agreement with previous data (Leuzzi et al.,
2016), in the absence of WRNIP1, nascent strands got degraded, resulting in a reduced IdU/CldU tract
length ratio (Figure S1A). However, this effect could be completely reverted when either of the fork remod-
elers ZRANB3 or HLTF is codepleted with WRNIP1 (Figures 1B and S1B), suggesting that WRNIP1 acts
downstream of fork reversal. Moreover, we also saw a complete restoration of fork stability when RAD51
was depleted on top of WRNIP1 (Figures 1B and S1B). Given RAD51’s essential role in the promotion of
fork reversal (Zellweger et al., 2015), this finding further suggests that WRNIP1, as BRCA2, protects stalled
replication forks after they have undergone fork reversal.
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Figure 1. WRNIP1 Protects Reversed Replication Forks in a Different Way Than BRCA2
(A) Scheme of DNA fiber labeling assay.
(B) Replication fork degradation analysis upon knock-down of WRNIP1 and codepletion of factors involved in replication
fork reversal.
(C) Replication fork degradation analysis upon knock-down of WRNIP1 (left) or BRCA2 (right) in the absence or
presence of the MRE11 exonuclease inhibitor mirin, the MRE11 endonuclease inhibitor PFM01, or upon codepletion
of MRE11.
Each dot represents an independent biological replicate. Values and gray bars indicate mean. Statistical analysis: one-
way ANOVA with Sidak’s correction for multiple comparisons (****, p < 0.0001; *, p < 0.1; ns, not significant). Scatterplots
of one representative experiment and western blots showing depletion efficacies can be found in Figure S1. CldU, 5-
chloro-20-deoxyuridine; IdU, 5-iodo-20-deoxyuridine; HU, hydroxyurea; RNAi, RNA interference; si, siRNA.
See also Figure S1 and Tables S1, S3, and S4.
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Since the inhibition of nucleases that are canonically involved in the processing of double-strandedDNAends,
such as MRE11, CtIP, and EXO1, can alleviate the fork degradation phenotype associated with knock-down
of BRCA2 (Lemac¸on et al., 2017; Schlacher et al., 2011), it is assumed that BRCA2 protects the
protruded reversed arm, presumably by promoting the assembly of a RAD51 filament (Mijic et al., 2017).
This notion is consistent with the observation that inhibition of MRE11’s 30–50 exonuclease activity by mirin
prevented the BRCA2 depletion-associated fork degradation phenotype to the same extent as a complete
depletion ofMRE11 by RNA interference, whereas theMRE11 endonuclease inhibitor PFM01 only led to a par-
tial restoration of fork stability (Figure 1C, right panel; S1C, and S1D). In surprising contrast, fork degradation
upon knock-down of WRNIP1 was prevented by depletion of MRE11 or inhibition of MRE11’s endonuclease
activity by PFM01, whereas inhibitingMRE11’s exonuclease activity bymirin had only a veryminor rescue effect
(Figures 1C, left panel; S1C, and S1D). Our findings hence suggest that, in contrast to what has been proposed
previously, WRNIP1’s and BRCA2’s fork protection functions seem to be mechanistically distinct.
WRNIP1 Protects Reversed Replication Forks from SLX4-Mediated Endonucleolytic
Cleavage
In light of these observations, we then wondered whether WRNIP1, instead of protecting the protruded arm
of a reversed fork, could rather shield its junction point, e.g., from the attack of structure-specific
endonucleases. Over the last years, a number of endonucleases that are able to target four-way junctions
have been discovered (Dehe´ and Gaillard, 2017). Several of them, namely SLX1, MUS81-EME1, and XPF-
ERCC1, form a multiprotein complex with the scaffold protein SLX4 (Fekairi et al., 2009; Mun˜oz et al., 2009;
Svendsen et al., 2009). In vitro, they have partially overlapping substrate preferences and can influence each
other’s biochemical activities (Wyatt et al., 2013, 2017). In vivo, however, they do not seem to form a constitutive
complex throughout all cell cycle phases. Notably, cells synchronized in G1/S phase contain a pool of MUS81-
EME1 that does not cofractionate with the rest of the complex on a sucrose gradient (Wyatt et al., 2017), sug-
gesting the existence of functional subcomplexes. In addition to being able to cleave recombination-associ-
ated Holliday junctions, SLX4 has also been reported to promote endonucleolytic processing of replication
forks (for review see Guervilly and Gaillard, 2018). Although this seems to primarily involve MUS81-EME1
and SLX1, SLX4-promoted fork processing by XPF-ERCC1 was recently reported (Be´tous et al., 2018).
To assess whether WRNIP1 may be involved in preventing SLX4-driven unscheduled fork processing, we
codepleted WRNIP1 and SLX4 and employed the same fiber labeling approach as described earlier.
Depletion of SLX4 completely suppressed the fork degradation phenotype resulting from depletion of
WRNIP1 (Figures 2A and S2A), suggesting that in the absence of WRNIP1, reversed forks can become
the target of endonucleolytic cleavage. To address which of the SLX4-associated nucleases are involved
in fork processing, we then individually codepleted SLX1, XPF, and MUS81 with WRNIP1. Whereas/while
codepletion of MUS81 had only a minor effect on fork stability, we could observe a complete alleviation
of fork degradation upon codepletion of XPF and a partial alleviation upon codepletion of SLX1 (Figures
2A and S2A). These findings fit to previous observations that a major part of MUS81-EME1 is not associated
with SLX4 during S phase (Wyatt et al., 2017) and suggest that in the absence of WRNIP1, reversed repli-
cation forks may be cleaved by SLX1 and XPF-ERCC1 in an SLX4-dependent manner.
We then wondered whether WRNIP1 could protect reversed replication forks by directly binding to them.
To address this possibility, we purified N-terminally Flag-tagged WRNIP1 from Sf9 insect cells (Figure S2B)
and tested its ability to bind to a variety of DNA substrates in vitro. Using electrophoretic mobility shift
assays (EMSAs), we could observe binding of purified WRNIP1 to a DNA structure mimicking a reversed
replication fork, whereas it did not show any affinity for single-stranded or double-stranded DNA or for
a substrate that resembles a canonical replication fork (Figure 2B). Importantly, WRNIP1’s ability to bind
to four-way junction substrates required neither an intact ubiquitin-binding zinc finger (UBZ) domain
(Bish and Myers, 2007) nor a functional AAA + ATPase domain (Hishida et al., 2002), because the UBZ
domain variant WRNIP1 D37A (Crosetto et al., 2008) and the Walker A and B variants K274A and E329Q
were still able to bind to DNA (Figures S2B–S2D).
WRNIP1 Physically and Functionally Interacts with SLX1-SLX4
Given the observed restoration of fork stability upon codepletion of SLX4 withWRNIP1, andWRNIP1’s abil-
ity to bind to four-way junction substrates, we next tested whether WRNIP1 was able to protect a four-way
junction substrate from endonucleolytic cleavage in vitro. To do so, we titrated WRNIP1 into a nuclease
assay with a four-way junction substrate and purified SLX1-SLX4. With increasing amounts of WRNIP1,
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the cleavage product decreased, suggesting that WRNIP1 can indeed protect four-way junctions from
SLX1-SLX4 cleavage (Figure 3A). In line with their ability to bind to four-way junction substrates (Figure S2D),
a similar effect was also observed when the UBZ or ATPase domain variants were added to SLX1-SLX4
cleavage reactions (Figure S3A).
Strikingly, the protective effect of WRNIP1 seems to be specific for reactions with SLX1-SLX4, because titration
of WRNIP1 into a nuclease assay with a nicked four-way junction substrate and purified MUS81-EME1 did not
influence MUS81-EME1 cleavage (Figure 3B). Since WRNIP1 has a similar binding affinity for nicked four-way
junctions than for intact four-way junctions (Figure S3B), we then wondered whether the observed specificity
could stem from a direct interaction between WRNIP1 and SLX1-SLX4. To address this possibility, we immobi-
lized purified SLX1-SLX4 on beads and added purified WRNIP1. In this coimmunoprecipitation experiment we
could observe a robust direct interaction between WRNIP1 and the SLX1-SLX4 complex (Figure 3C).
Taken together, our data suggest that WRNIP1 protects the junction point of reversed replication forks
from SLX4-dependent endonucleolytic cleavage, presumably through its ability to directly bind to these
DNA structures and to interact with SLX1-SLX4. In contrast, WRNIP1 cannot protect from MUS81-EME1
cleavage in vitro, and depletion of MUS81 on top of WRNIP1 does not restore fork stability (Figures 2A
and S2A). We further show that the UBZ and ATPase domains of WRNIP1 are dispensable for its protective
function in vitro, which is in line with our observation that the UBZ and ATPase domain mutants are able
to restore cellular fork stability to a similar extent as the wild-type construct (Figures 3D and S3C).
Fork Resection in the Absence of Both WRNIP1 and BRCA2 Requires Endonucleolytic and
Exonucleolytic Cleavage Steps
Our data so far suggest that WRNIP1 acts in a different branch of fork protection than BRCA2 by protecting
the junction point, rather than the protruded arm, of a reversed fork. Unscheduled SLX4-mediated fork pro-
cessing alone, however, cannot readily explain the extensive fork degradation phenotype associated with
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Figure 2. WRNIP1 Protects Reversed Replication Forks from SLX4-Dependent Nucleolytic Cleavage
(A) Replication fork degradation analysis upon knock-down of WRNIP1 and codepletion of SLX4 or associated nucleases.
Each dot represents an independent biological replicate. Values and gray bars indicate mean. Statistical analysis: one-
way ANOVA with Sidak’s correction for multiple comparisons (****, p < 0.0001; **, p < 0.01; ns, not significant).
Scatterplots of one representative experiment and western blots showing depletion efficacies can be found in Figure S2.
(B) EMSA to monitor binding of increasing amounts of WRNIP1 to ssDNA (left), dsDNA (second from left), a replication
fork-like substrate (second from right), and a four-way junction substrate (right).
See also Figure S2 and Tables S1 and S2–S4.
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the depletion of WRNIP1. Since our data show that MRE11’s exonuclease activity is not responsible for
long-range fork resection in the absence of WRNIP1 (Figure 1C), we wondered whether the 50–30 exonu-
clease DNA2 that is known to resect unprotected forks upon BOD1L or CtIP depletion (Higgs et al.,
2015; Przetocka et al., 2018) could play a role in fork resection upon WRNIP1 knock-down. Indeed, both
the depletion of DNA2 and the inhibition of DNA2 by C5 restored fork stability in the absence of WRNIP1,
whereas knock-down of the 50–30 exonuclease EXO1 had no effect on fork stability (Figures 4A and S4A). In
the absence ofWRNIP1, SLX4-associated endonucleases may hence target unprotected reversed forks and
thereby generate a substrate for extensive DNA2-mediated resection.
These data also underline the difference in fork protection between WRNIP1 and BRCA2, because neither
depletion of DNA2 nor use of the DNA2 inhibitor C5 could alleviate the fork degradation phenotype of
BRCA2-depleted cells (Lemac¸on et al., 2017; Przetocka et al., 2018).
To further delineate these two apparently distinct branches of fork protection, we checked the effect of
SLX4 and MUS81 depletion on fork stability in cells lacking BRCA2 (Figures 4B and S4B). If WRNIP1 and
BRCA2 were to act independently of each other, also in the absence of BRCA2, WRNIP1 should presumably
be able to protect the junction point of a reversed fork from SLX4-dependent cleavage. In agreement with
this idea, we observed that fork degradation in BRCA2-depleted cells could not be alleviated by codeple-
tion of SLX4 (Figures 4 and S4B).
On the other hand, codepletion of MUS81 or EME1 with BRCA2 could largely restore fork stability (Figures
4B and S4B). In this context, it should be noted that reversed forks are not a substrate for MUS81-EME1,
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Figure 3. WRNIP1 Interacts Physically and Functionally with SLX1-SLX4
(A) Endonucleolytic cleavage assay with SLX1-SLX4 in the presence of increasing amounts of WRNIP1.
(B) Endonucleolytic cleavage assay with MUS81-EME1 in the presence of increasing amounts of WRNIP1.
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(****, p < 0.0001; **, p < 0.01; ns, not significant). Scatterplots of one representative experiment and western blots
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See also Figure S3 and Tables S1 and S2–S4.
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which prefers nicked or resected four-way junctions. In the absence of BRCA2, however, MRE11 exonu-
clease activity may extensively resect reversed replication forks and, hence, convert them into substrates
preferred by MUS81-EME1. Given our in vivo (Figure 2A) and in vitro (Figure 3B) data, we would not expect
WRNIP1 to be able to protect resected reversed replication forks from MUS81-EME1 cleavage.
Collectively, our data indicate that BRCA2 andWRNIP1 are part of two distinct branches of the fork protec-
tion pathway. However, while their loss leads to the generation of different types of DNA structures that are
targeted by distinct sets of nucleases, extensive fork resection seems to require, in both cases, an exonu-
cleolytic and endonucleolytic cleavage step.
Only the Short Variant of WRNIP1 Is Able to Bind to DNA and Protect Stalled Replication
Forks
In the cell, WRNIP1 transcripts are spliced into two major isoforms that give rise to a 640 amino acid-long
protein (used throughout this study and referred to as WRNIP1) and a 665 amino acid-long protein (herein
after referred to as WRNIP1L), respectively. These two variants differ only by a 25 amino acid-long insertion
between the Walker B motif and the ATP-binding arginine finger (Figure 5A). Intriguingly, this insertion is
highly conserved, with 84% of amino acid identity between human WRNIP1 and Escherichia coli MgsA,
which is clearly above and beyond the, already remarkable, overall conservation (25% of identity) between
the human and bacterial protein (Kawabe et al., 2001). Surprisingly, although the large majority of tran-
scripts in the cell encode the long isoform (Figures S5A–S5C), WRNIP1L displayed poor binding to a
four-way branched DNA structure (Figures 5B and S5D) and was unable to protect it from SLX1-SLX4-
dependent cleavage when titrated into a nuclease assay (Figure 5C).
Making use of this naturally occurring DNA binding-deficient variant we tested our hypothesis that WRNIP1
shields reversed replication forks by directly binding to them. In agreement with this prediction, degradation
of replication forks caused by depletion of endogenous WRNIP1 could be prevented by expressing recom-
binant WRNIP1 but not WRNIP1L (Figure 5D and S5E). Moreover, fork degradation was observed only after
the isoform-specific depletion of the short, but not the long, isoform of WRNIP1 (Figures 5D and S5E).
Taken together, these findings indicate that the short, but not the long, variant ofWRNIP1 is involved in fork
protection from SLX4-mediated cleavage and suggest that WRNIP1’s ability to bind to branched DNA sub-
strates is a prerequisite for this function.
DISCUSSION
In this study, we investigate the molecular mechanism of how WRNIP1 can protect stalled replication
forks and find that WRNIP1 exerts its protective function after stalled forks have undergone reversal.
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This conclusion is based on our observation that fork stability in WRNIP1-deficient cells is restored
upon inactivation of the replication fork remodelers ZRANB3 and HLTF or the recombinase RAD51.
It is of note, however, that the latter finding is in conflict with published data that show no alleviation
of the WRNIP1 depletion–associated fork degradation phenotype upon knock-down of RAD51 (Leuzzi
et al., 2016). In light of RAD51’s dual role in the promotion of fork reversal and the protection of
reversed forks (Mijic et al., 2017; Zellweger et al., 2015), we suspect that different knock-down effi-
ciencies could be the explanation for the discrepancy between our data and the study by Leuzzi and
colleagues. In agreement with this hypothesis, an incomplete knock-down of RAD51 was shown to
cause a situation, in which fork reversal is still possible, but RAD51 levels are too low to efficiently pro-
tect reversed forks (Bhat et al., 2018). Conversely, a complete knock-down of RAD51 was reported
to entirely block fork reversal (Mijic et al., 2017). In the aforementioned WRNIP1 study, a RAD51 inhib-
itor that selectively prevents RAD51 filament formation was also unable to prevent the WRNIP1 deple-
tion-associated phenotype (Leuzzi et al., 2016). This finding is however not in contradiction with our
data, as stable RAD51 filaments are not required for the formation of reversed replication forks
(Mijic et al., 2017).
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Figure 5. WRNIP1, but Not WRNIP1L, Can Protect Reversed Replication Forks
(A) Alignment of WRNIP1’s central ATPase domain from a variety of species. Highlighted in bold are the Walker B motif
(left) and the arginine finger (right), shaded in gray is the 25 amino acid-long insertion found in WRNIP1L (665 amino
acid protein), but not in WRNIP1 (640 amino acid protein). Symbols underneath reflect amino acid conservation, with
asterisks marking identical amino acids and colons indicating conservation of chemical character. Hs, Homo sapiens;
Mm, Mus musculus; Dd, Dictyostelium discoideum; Sc, Saccharomyces cerevisiae; Sp, Schizosaccharomyces pombe;
Ec, Escherichia coli.
(B) EMSA to monitor binding of increasing amounts of WRNIP1L to a four-way junction substrate.
(C) Endonucleolytic cleavage assay of SLX1-SLX4 in the presence of increasing amounts of WRNIP1L. Dashed line
indicates that lanes were left out for clarity.
(D) Replication fork degradation analysis upon knock-down of WRNIP1 and complementation with cDNAs expressing the
short (WRNIP1) or long (WRNIP1L) isoform. On the right, knock-down of WRNIP1 (short*) or WRNIP1L (long*) using
isoform-specific siRNAs. Each dot represents an independent biological replicate. Values and gray bars indicate mean.
Statistical analysis: one-way ANOVAwith Sidak’s correction for multiple comparisons (****, p < 0.0001; ns, not significant).
Scatterplots of one representative experiment and western blots showing depletion and expression efficacies can be
found in Figure S5. 4-WJ, four-way junction; n-ds, nicked duplex DNA; si, siRNA.
See also Figure S5 and Tables S1 and S2–S4.
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We further show that, even though WRNIP1, as BRCA2, acts downstream of replication fork reversal, the
two proteins exert their protective function in different ways. Since mirin, an inhibitor of MRE11’s exonu-
clease activity, was found to revert the fork degradation phenotype of BRCA2-deficient cells, it was pro-
posed that BRCA2 and RAD51 protect the end of the regressed arm from MRE11 exonuclease-mediated
resection (Kolinjivadi et al., 2017; Lemac¸on et al., 2017; Mijic et al., 2017; Taglialatela et al., 2017). In
contrast, we find that mirin has no effect on restoring stalled fork stability in WRNIP1-deficient cells.
Instead, we show that depletion of SLX4 or its associated structure-specific endonucleases SLX1 and
XPF-ERCC1 restores fork stability in the absence of WRNIP1, suggesting that WRNIP1 protects the junction
point of a reversed fork, rather than the end of the protruded arm.
In line with this hypothesis, our in vitro data indicate that WRNIP1 can bind to DNA substrates that mimic
reversed replication forks and protect them from endonucleolytic cleavage by SLX1-SLX4. In contrast to a
previous study that reported a weak, ATP-dependent binding of WRNIP1 to primer/template junctions and
replication fork-like structures (Yoshimura et al., 2009), we did not detect any binding to single- or double-
stranded DNA nor replication fork-like structures. Moreover, in our experimental set-up, binding of
WRNIP1 to four-way junction substrates was independent of the presence of ATP, and Walker A and B var-
iants of WRNIP1 could bind to four-way junction substrates, and protect them from SLX1-SLX4 cleavage, to
a similar extent as the wild-type protein. Accordingly, complementation of WRNIP1-depleted cells with
Walker A and B domain mutants could restore fork stability to a similar extent as complementation with
a wild-type construct. These findings are also in agreement with a previous study that reports restoration
of fork stability with a WRNIP1 variant that has a single amino acid change in between the Walker A and
B motifs (T294A) (Leuzzi et al., 2016).
Since protein ubiquitination plays an important role in the context of replication fork reversal (Vujanovic
et al., 2017), we also addressed whether WRNIP1’s UBZ domain (Bish and Myers, 2007) was required for
its role in fork protection. The UBZ variant D37A WRNIP1 (Crosetto et al., 2008) proved, however, able
to bind to DNA substrates in vitro, to protect four-way junctions from SLX1-SLX4 cleavage and to comple-
ment WRNIP1-depleted cells to a large extent, suggesting that WRNIP1’s ability to bind to ubiquitin plays
at most a minor role in the context of fork protection, possibly to help recruit WRNIP1 more efficiently to
sites of DNA replication (Crosetto et al., 2008).
In contrast to what we found in cells lacking WRNIP1, replication fork stability could be restored in
BRCA2-depleted cells by knocking-down MUS81 or EME1 but not SLX4. These different genetic interac-
tions may be explained by the distinct substrate selectivity of MUS81-EME1 and SLX1-SLX4. Whereas/
while recombinant SLX1-SLX4 efficiently processes intact four-way junctions, recombinant MUS81-EME1
is much more active on four-way junctions that are nicked or contain one single-stranded arm (Gaillard
et al., 2003; Wyatt et al., 2013). We hypothesize that the latter structure could be generated at reversed
replication forks in the absence of BRCA2 as a result of MRE11-mediated resection of the protruded arm.
Although such a scenario is consistent with a recently published study where MUS81-EME1 was found
to drive unscheduled replication fork degradation in BRCA2-deficient cells (Rondinelli et al., 2017), it
may not seem consistent at first glance with another recent study that contests a role of BRCA2 in pro-
tecting forks from MUS81-mediated cleavage (Lemac¸on et al., 2017). It should be noted, however, that in
the latter study a modified fiber labeling protocol was employed to exclude forks that are unable to
restart after fork resection. Given MUS81’s important role in replication fork restart, as shown in the
same study, any restoration of fork stability in the absence of MUS81 could simply not be detected
with this approach.
Overall, our data would be in agreement with a model in which WRNIP1 and BRCA2 act in two parallel
branches of the fork protection pathway that are both required for the efficient protection of reversed
replication forks (Figure 6). We envision that in the absence of WRNIP1, the junction point of a reversed
fork would remain unprotected and become a target of SLX4-mediated endonucleolytic cleavage.
After SLX4-mediated cleavage, the resulting broken fork could then serve as an entry point for
DNA2-mediated nucleolytic degradation that would lead to the extensive nascent DNA degradation
that we observe upon WRNIP1 depletion. In contrast, in the absence of BRCA2, the junction point of
the reversed fork would initially be protected from SLX4-mediated cleavage by WRNIP1. The
MRE11-mediated resection of the unprotected reversed arm, however, would generate a resected
reversed fork and, hence, a substrate for MUS81-EME1. In agreement with our in vivo and in vitro
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data, WRNIP1 would not be able to prevent MUS81-EME1 cleavage. MUS81-EME1 would therefore
be able to incise such a resected reversed fork and, thus, generate an entry point for further MRE11-
mediated nucleolytic degradation.
Taken together, we propose that in the absence of BRCA2 and WRNIP1 different DNA substrates are
generated at reversed forks but that the extensive nascent strand degradation in both cases depends
on the activity of exonucleases and structure-specific endonucleases. This model would imply that in the
absence of WRNIP1 and BRCA2 the endpoint of fork degradation is similar, although WRNIP1 and
BRCA2 are situated in two distinct branches of the fork protection pathway and protect replication forks
in a mechanistically distinct manner. Accordingly, a previous study and our own data (not shown) demon-
strate that codepletion of WRNIP1 and BRCA2 does not lead to an additive effect with respect to fork
degradation (Leuzzi et al., 2016).
Interestingly, the long isoform ofWRNIP1, WRNIP1L, which has a remarkably conserved 25 amino acid-long
insertion in the ATPase domain, is unable to bind to DNA and protect it from SLX1-SLX4 cleavage. More-
over, fork stability in WRNIP1-depleted cells cannot be restored by WRNIP1L, suggesting that although
WRNIP1L is the prevalent isoform in the cell, it is not the isoform that plays a role in fork protection. It
remains to be seen whether, from an evolutionary point of view, the fork protection function of WRNIP1
is a new acquisition or whether in other species this highly conserved region does not interfere with
WRNIP1’s ability to protect replication forks. It is of note that WRNIP1 seems to be a moonlighting protein
that, in addition to its function in the maintenance of genome stability, also plays a role in antiviral signaling
of double-stranded RNA (Tan et al., 2017). Interestingly, in the cited study the long isoform was used to
complement WRNIP1 knock-out cells, raising the possibility that the two isoforms could have entirely sepa-
rate functions with WRNIP1 playing a role in fork protection and WRNIP1L having a function in innate anti-
viral immunity.
Figure 6. Model Illustrating the Two Branches of Fork Protection That Are Dependent on BRCA2 and WRNIP1,
Respectively
See Discussion for details.
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Limitations of the Study
Based on our DNA fibers analyses and in vitro experiments, which suggest that the junction point of a
reversed fork becomes a target of SLX4-mediated endonucleolytic cleavage in the absence of WRNIP1,
we propose a direct role for WRNIP1 in the protection of reversed replication forks.
One prediction of our model would be the formation of double-strand breaks at stalled replication forks
in the absence of WRNIP1. Unexpectedly, however, we were not able to detect a significant increase in
double-strand breaks upon WRNIP1 depletion, possibly because breaks are formed very transiently, and
steady-state levels are therefore very low. More sensitive methods will have to be used in the future to
address this issue.
It should also be stressed that DNA fiber assays have an intrinsically low resolution and can therefore only
provide an endpoint result. In order to delineate the exact series of nucleolytic events taking place at the
site of a stalled replication fork, additional approaches, such as the visualization of replication forks by elec-
tron microscopy, will be required to unravel further mechanistic details.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.10.010.
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Figure S1. WRNIP1 protects reversed replication forks in a different way than BRCA2, Related to 
Figure 1. (A) Left: Replication fork degradation analysis in cells depleted of WRNIP1 using different 
siRNA sequences. Each dot represents an independent biological replicate. Values and grey bars 
indicate mean. Statistical analysis: one-way ANOVA with Sidak's correction for multiple 
comparisons. Middle: scatter plot of one representative experiment. Each dot represents one 
replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: 
western blots. (B) Replication fork degradation analysis upon knock-down of WRNIP1 and co-
depletion of factors involved in replication fork reversal. Left: scatter plot of one representative 
experiment. Each dot represents one replication fork. Values and red bars indicate median. 
Statistical analysis: Kruskal-Wallis test. Right: western blots. (C) Replication fork degradation 
analysis upon knock-down of WRNIP1 (left) or BRCA2 (right) in the absence or presence of the 
MRE11 exonuclease inhibitor mirin, the MRE11 endonuclease inhibitor PFM01 or upon co-
depletion of MRE11. Left: scatter plots of one representative experiment. Each dot represents one 
replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: 
western blots. (D) Replication fork degradation analysis in cells depleted of indicated nucleases or 
treated with indicated inhibitors. Each dot represents one replication fork. Values and grey bars 
indicate median. Statistical analysis: Kruskal-Wallis test. si, siRNA; WB, western blot; p values (****, 
p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, not significant). 
 
 
  
 
 
Figure S2. WRNIP1 protects reversed replication forks from SLX4-dependent nucleolytic cleavage, 
Related to Figure 2. (A) Replication fork degradation analysis upon knock-down of WRNIP1 and co-
depletion of SLX4 and associated nucleases. Top: scatter plots of one representative experiment. 
Each dot represents one replication fork. Values and red bars indicate median. Statistical analysis: 
Kruskal-Wallis test. Bottom: western blots. (B) InstantBlue-stained SDS gels of purified Flag-
WRNIP1 variants. (C) ATPase activity of wild-type WRNIP1 and the Walker A and B variants K274A 
and E329Q in the absence of DNA (–) or in the presence of ssDNA (ss), dsDNA (ds) or a four-way 
junction substrate (4WJ), as measured by release of inorganic phosphate (Pi) from radio-labelled γ-
32P-ATP in thin-layer chromatography. Error bars depict standard deviation from three independent 
experiments. (D) EMSA showing WRNIP1 variants' ability to bind to a four-way junction substrate. 
si, siRNA; WB, western blot; p values (****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, 
not significant). 
 
 
Figure S3. ATP- and ubiquitin binding are largely dispensable for WRNIP1’s role at stalled DNA 
replication forks, Related to Figure 3. (A) Endonucleolytic cleavage assay of SLX1-SLX4 in the 
presence of increasing amounts of WRNIP1 variants.  (B) EMSA showing binding of wild-type 
WRNIP1 to an intact four-way junction substrate (left) and a nicked four-way junction substrate 
(right). (C) Replication fork degradation analysis in WRNIP1-depleted cells, complemented with 
WRNIP1 variants. Endogenous WRNIP1 was depleted by siRNA targeting the 3´-UTR. Left: scatter 
plot of one representative experiment. Each dot represents one replication fork. Values and red 
bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. si, siRNA; WB, 
western blot; p values (****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, not significant). 
 
 
 
 
  
 
 
Figure S4. Fork resection requires endonucleolytic and exonucleolytic cleavage steps, Related to 
Figure 4. (A) Replication fork degradation analysis upon knock-down of WRNIP1 in the absence or 
presence of the DNA2 inhibitor C5 or upon co-depletion of DNA2 or EXO1. Left: scatter plots of 
one representative experiment. Each dot represents one replication fork. Values and red bars 
indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. (B) Replication fork 
degradation analysis upon knock-down of BRCA2 and co-depletion of SLX4, MUS81 or EME1. Left: 
scatter plots of one representative experiment. Each dot represents one replication fork. Values 
and red bars indicate median. Statistical analysis: Kruskal-Wallis test. Right: western blots. Please 
note that the left half of the upper western blot of Figure S4B is identical to the left half of the left 
western blot in Figure S2A, since the experiments were done in parallel and the control samples 
used were the same. si, siRNA; WB, western blot; p values (****, p < 0.0001; ***, p < 0.001; **, p < 
0.01; *, p < 0.1; ns, not significant). 
 
 
Figure S5. WRNIP1, but not WRNIP1L, can protect reversed replication forks, Related to Figure 5. 
(A) End-point RT PCR-based analysis of isoform abundance of WRNIP1/WRNIP1L in U2OS cells. 
Upper panel depicts the analysed locus. Lower panel shows electrophoretic analysis of the end-
point PCR reaction on a cDNA library. (B) Western blot showing comparison of ectopically 
expressed untagged WRNIP1 isoforms to endogenous WRNIP1 from U2OS, RPE-1 and HEK 293T 
cell lines. (C) Expression levels of WRNIP1 isoforms in different tissues. Graph was generated using 
the ISOexpresso tool that utilises TCGA database. (D) InstantBlue-stained SDS gel of purified wild-
type WRNIP1L. (E) Replication fork degradation analysis upon knock-down of WRNIP1 and 
complementation with cDNAs expressing the short (WRNIP1) or long (WRNIP1L) isoform (left 
panels). Right panels, knock-down of WRNIP1 (short isoform) or WRNIP1L (long isoform) using 
isoform-specific siRNAs. Top: scatter plots of one representative experiment. Each dot represents 
one replication fork. Values and red bars indicate median. Statistical analysis: Kruskal-Wallis test. 
Bottom: western blots. si, siRNA; WB, western blot; p values (****, p < 0.0001; ***, p < 0.001; **, p 
< 0.01; *, p < 0.1; ns, not significant).  
Supplemental Tables S2-S4 
 
 
Table S2. Oligos used in this study, Related to Figures 2, 3 and 5. 
 
name sequence (5´–3´) 
X01 GACGCTGCCGAATTCTACCAGTGCCTTGCTAGGACATCTTTGCCCACCTGCAGGTTCACCC 
X01c GGGTGAACCTGCAGGTGGGCAAAGATGTCCTAGCAAGGCACTGGTAGAATTCGGCAGCGTC 
X02 TGGGTGAACCTGCAGGTGGGCAAAGATGTCCATCTGTTGTAATCGTCAAGCTTTATGCCGTT 
X02.1/2 TGGGTGAACCTGCAGGTGGGCAAAGATGTCC 
X03 GAACGGCATAAAGCTTGACGATTACAACAGATCATGGAGCTGTCTAGAGGATCCGACTATCGA 
X03.1/2 CATGGAGCTGTCTAGAGGATCCGACTATCGA 
X03.1/2_2 GAACGGCATAAAGCTTGACGATTACAACAGAT 
X04 ATCGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAGGCACTGGTAGAATTCGGCAGCGT 
 
 
  
Table S3. siRNAs used in this study, Related to Figures 1-5. 
 
name target gene target region reference sequence (5'-3') 
siControl – – Microsynth  (neg. control) 
AGG UAG UGU AAU CGC CUU 
G 
siBRCA2 BRCA2 BRCA2 mRNA: 3401 - 3421 
(Mijic et al., 
2017) 
AAC UGA GCA AGC CUC ACU 
CAA 
siHLTF HLTF HLTF mRNA: 567 - 585 
(Blastyak et al., 
2010) 
GGU GCU UUG GCC UAU AUC 
A 
siMRE11 #1 MRE11 MRE11 mRNA: 2436 - 2454 this study 
GAG CAU AAC UCC AUA AGU 
A 
siMRE11 #2 MRE11 MRE11 mRNA: 1793 - 1811 
(Yuan and Chen, 
2010) 
GGA GGU ACG UCG UUU 
CAG A 
siMUS81 MUS81 MUS81 mRNA: 1825 - 1843 
(Di Marco et al., 
2017) 
CAG CCC UGG UGG AUC GAU 
A 
siRAD51 RAD51 RAD51 mRNA: 1327 - 1345 
(Mijic et al., 
2017) 
GAC UGC CAG GAU AAA GCU 
U 
siSLX1 SLX1 SLX1 mRNA: 1047 - 1067 
(Muñoz et al., 
2009) 
UGG ACA GAC CUG CUG 
GAG AUU  
siSLX4 #1 SLX4 SLX4 mRNA: 5826 - 5848 
(Mutreja et al., 
2018) 
CGG CAU UUG AGU CUG CAG 
GUG AA 
siSLX4 #2 SLX4 SLX4 mRNA: 3181 - 3201 
(Mutreja et al., 
2018) 
AAA CGU GAA UGA AGC AGA 
AUU 
siWRNIP1 #1 WRNIP1 WRNIP1 mRNA: 1099 - 1117 this study 
CAA CAA AUG CCA AGA CAA 
A 
siWRNIP1 #2 WRNIP1 WRNIP1 mRNA: 1639 - 1657 this study 
CAG AGA AUG ACG UGA 
AGG A 
siWRNIP1 #3 WRNIP1 
WRNIP1 mRNA: 
2301 - 2319  
(3' UTR) 
this study UUA GAA CAG ACC AAC AUU U 
siWRNIP1L WRNIP1  (long isoform) 
2-20 nt of the 
insertion this study 
ACA CUU UCC UUC CUC ACG 
U 
siWRNIP1S WRNIP1  (short isoform) 
-4 to +14 
around the 
insertion site 
this study CAG GUC AAC GCU GCU CUU C 
siZRANB3 ZRANB3 ZRANB3 mRNA: 2127 - 2145 this study 
UCA GAA AGA CAC CUC CAA 
A 
siXPF XPF XPF mRNA:  341 - 359 
(Mutreja et al., 
2018) 
GUA GGA UAC UUG UGG 
UUG A 
siDNA2 DNA2 DNA2 mRNA: 3267 - 3285 
(Thangavel et 
al., 2015) 
CAG UAU CUC CUC UAG CUA 
G 
siEME1 EME1 EME1 mRNA: 328 - 345 
(Pepe and West, 
2014) 
GCU AAG CAG UGA AAG UGA 
A 
siEXO1 EXO1 EXO1 mRNA: 2243 - 2261  
(Przetocka et 
al., 2018) 
GCC UGA GAA UAA UAU GUC 
U 
 
Note that siWRNIP1 #3 was used in all experiments and is referred to as “siWRNIP1”.  
Table S4. Antibodies used in this study, Related to Figures 1-5. 
 
antibodies manufacturer catalogue number source use dilution 
primary antibodies 
WRNIP1 G-2 Santa-Cruz Biotechnology sc-377402 mouse WB 1:1000 
WRNIP1 N-17 Santa-Cruz Biotechnology sc-55437 goat WB 1:1000 
Flag M2 Sigma-Aldrich F1804 mouse WB 1:1000 
His GE Healthcare 27-4710-01 mouse WB/IP 1:1000 
HLTF GeneTex GTX114776 rabbit WB 1:1000 
ZRANB3 ProteinTech 23111-1-AP rabbit WB 1:1000 
RAD51 Santa-Cruz Biotechnology sc-8349 rabbit WB 1:1000 
MRE11 Novus Biological NB100-142 rabbit WB 1:1000 
BRCA2 EMD Millipore OP95 mouse WB 1:1000 
SLX4 Bethyl Laboratories A302-270A rabbit WB 1:1000 
MUS81 Sigma-Aldrich M1445 mouse WB 1:1000 
XPF Bethyl Laboratories A301-315A rabbit WB 1:1000 
DNA2 Abcam ab96488 rabbit WB 1:1000 
EME1 Santa-Cruz Biotechnology sc-53275 mouse WB 1:1000 
EXO1 Bethyl Laboratories A302-640A rabbit WB 1:1000 
Actin Santa-Cruz Biotechnology sc-47778 mouse WB 1:2000 
Tubulin Santa-Cruz Biotechnology sc-9104 mouse WB 1:1000 
BrdU/CldU Abcam ab6326 rat DNA fibres 1:500 
BrdU/IdU Becton Dickinson 347580 mouse DNA fibres 1:80 
secondary antibodies 
anti-Mouse-HRP Amersham NA931 sheep WB 1:5000 
anti-Rabbit-HRP Amersham NA934 donkey WB 1:5000 
anti-Goat-HRP Santa-Cruz Biotechnology sc-2354 mouse WB 1:5000 
anti-Mouse-Alexa488 Invitrogen A-11029 goat DNA fibres 1:300 
anti-Rat-Cy3 Jackson ImmunoResearch 712-165-153 donkey 
DNA 
fibres 1:300 
 
  
Transparent Methods 
 
Plasmids and baculoviruses 
WRNIP1 cDNA was purchased from Mammalian Gene Collection (Dharmacon) as a bacterial stab. 
The cDNA was cloned into pDONR221™ GATEWAY® entry vector (Invitrogen) according to the 
manufacturer's protocol and transformed into competent bacteria. WRNIP1L was cloned by a 
series of PCR reactions using WRNIP1-pDONR221 as a template. All entry vectors were analysed 
by restriction digest reactions and sequencing (Microsynth). GATEWAY® destination vectors were 
generated according to the manufacturer's protocol. Site-directed mutagenesis was performed 
according to the original idea of Stratagene (QuikChange® Site-Directed Mutagenesis, Stratagene) 
on GATEWAY® entry vectors. Bacmids and baculoviruses were generated using the Bac-to-Bac® 
Baculovirus Expression System (Invitrogen) approach.  
 
Protein purifications 
All human WRNIP1 variants were purified from Sf9 insect cells. A liquid culture at a density of 2x106 
cells/ml was infected with baculoviruses at an MOI = 1. Cells were incubated with shaking at 25 °C 
for 48 hours, and harvested and lysed in 5 PCV (packed-cell volume) of Lysis Buffer (50 mM Na-
phosphate pH 7.0, 150 mM NaCl, 10% glycerol, 0.1% NP-40, 1 mM TCEP, 0.5 mM EDTA), supplied 
with protease inhibitors cocktail (Roche) for 30 minutes on ice with intermittent vortexing. Lysates 
were spun down at 4 °C in a Sorvall™ WX+ (Thermo Scientific) ultracentrifuge equipped with a T-
865 rotor at 37,500 rpm for 1 hour. Supernatant was collected and filtered through 0.45 μm and 
0.22 μm filters. Resulting cell lysates were incubated with 0.01 volumes of equilibrated Flag M2 
beads (Sigma Aldrich) for 2 hours at 4 °C with rotation. Afterwards, beads were washed 3 times for 
10 minutes in 10 ml of the Lysis Buffer at 4 °C with rotation, followed by 3 washes with Storage 
Buffer (Lysis Buffer minus EDTA). Afterwards, bound proteins were eluted twice with 5 beads 
volumes of the Storage Buffer supplemented with 200 ng/μl 3x FLAG® peptide (Sigma) for 1 hour 
at 4 °C, with rotation. Flag-IP eluates were filtered on 0.22 μm spin columns (Bio-Rad), aliquoted, 
snap-frozen and stored at -80 °C. Concentration was estimated from quantification of SDS-PAGE, 
followed by calculations based on a BSA standard curve. 
Human SLX1-SLX4 was purified from bacteria as a complex of His-tagged full-length SLX1 and the 
His-tagged CCD domain of SLX4, as described previously (Fekairi et al., 2009). 
MUS81-EME1 was purified from bacteria, as described previously (Di Marco et al., 2017). 
 
DNA substrates 
All oligonucleotides used for DNA substrate preparation were synthesised by Microsynth and are 
listed in Table S2. Oligonucleotide X01 served as a basis for all substrates used in this study and 
was therefore labelled on the 5´-end by fluorescein amidite during synthesis. 
Annealing of DNA substrates was done in a buffer containing 10 mM Tris-HCl pH 8.0, 50 mM NaCl 
and 10 mM MgCl2. Oligonucleotides were mixed, incubated for 5 minutes at 95 °C and then 
allowed to cool down to room temperature.  
DNA substrates were composed of the following oligonucleotides: 
o ssDNA: X01 
o dsDNA: X01, X01c 
o replication fork: X01, X02.1/2, X03.1/2, X04 
o 4-way junction: X01, X02, X03, X04 
o nicked 4-way junction: X01, X02, X03.1/2, X03.1/2_2, X04  
 
DNA binding 
DNA binding was done in 10 μl reactions containing 1 μl of DNA substrate (final concentration: 5 
nM) and 9 μl of protein dilution. Reactions were incubated on ice for 20 minutes, followed by 
addition of loading buffer (final: 3.5% Ficoll, 10 mM Tris-Cl pH 7.5, 10 mM EDTA, Xylene cyanol) 
and analysis by native gel electrophoresis using 0.5X TBE 6% polyacrylamide gels at room 
temperature. The gels were scanned using a Typhoon™ FLA9500 (GE Healthcare) scanner. 
 
ATPase activity 
ATPase activity was measured in 5 μl reactions containing 5 mM MgCl2, 0.01 mM ATP, 0.033 μM 
ATP - γ32P, 23.5 nM of protein and, optionally, 50 nM of a DNA substrate. Reactions were 
incubated at 37 °C for 30 minutes and then stopped by addition of EDTA to a final concentration of 
50 mM. 1 μl of the sample was spotted on a PEI-Cellulose thin-layer chromatography plate (Merck), 
and the plates were resolved in a solution containing 0.15 M LiCl and 0.15 M formic acid. Resolved 
plates were air-dried, wrapped in cling film and analysed by autoradiography.  
 
In vitro four-way junction protection 
The reversed fork protection assay was done by titrating WRNIP1 into SLX1-SLX4 nuclease 
reactions. WRNIP1 was first pre-incubated with the DNA substrate (4 μl of WRNIP1 dilution, 1 μl of 
50 nM DNA) for 10 minutes on ice. Then a 5 μl mix of SLX1-SLX4 in SLX reaction buffer was added 
to have a final concentration of 25 mM Tris-HCl pH 7.5, 0.25 mM β-mercaptoethanol, 50 μg/ml BSA 
(New England Biolabs), and 0.5 mM MgCl2. Reactions were carried out at 37 °C for 10 minutes, 
deproteinised for 10 minutes at 37 °C with 2 mg/ml Proteinase K and 0.4% SDS and resolved by 
native PAGE through 8% polyacrylamide gels in 1x TBE. Gels were scanned using Typhoon™ 
FLA9500 (GE Healthcare) scanner.  
Reversed fork protection assays with MUS81-EME1 were essentially done the same, except that 
the ME1 reaction buffer was chosen such that the final reactions contained 25 mM Tris-HCl (pH 
7.5), 2.5 mM MgCl2 and 20 mM KCl. 
 
Co-IPs 
The purified complex of His-tagged full-length SLX1 and the His-tagged CCD domain of SLX4 was 
pre-incubated with Flag-tagged WRNIP1 in lysis buffer for 1h at 4°C. In the meantime, anti-His 
antibodies were bound to Protein G Sepharose Fast Flow beads (Sigma Aldrich) for 2h at 4°C. The 
SLX1-SLX4/WRNIP1 binding mix (or the control mix containing WRNIP1 only) was then added to 
the beads and incubated overnight at 4°C. Beads were then washed extensively in lysis buffer and 
boiled in 2x sample buffer. Bound proteins were analysed by western blotting. 
 
Mammalian cell culture 
All human cell lines were grown in DMEM (Dulbecco's Modified Eagle Medium, Gibco) supplied 
with 10% fetal bovine serum (Gibco) at 37 °C and 5% oxygen. For replicates of phenotypical 
analyses, cells of similar passage number were used (±2) to ensure reproducibility of conditions. Sf9 
insect cells were grown in HyClone™ SFX-Insect™ cell culture media (GE Healthcare) at 25 °C with 
shaking.  
 
Plasmid transfections 
Transfection of bacmids to Sf9 insect cells was done using TransIT®-LT1 Transfection Reagent 
(Mirus) according to the manufacturer's protocol. Human U2OS cells were transfected using 
jetPRIME® (Polyplus-transfection®) according to the manufacturer's protocol (10 μg plasmid DNA 
per ø10 cm culture dish; 1:3 (w/v) DNA:jetPRIME® ratio); medium was replaced after 6-8 hours.  
RNA interference 
Short interfering RNA duplexes were designed using Sfold (http://sfold.wadsworth.org/), unless 
otherwise stated, and synthesised at Microsynth. U2OS cells were transfected with siRNAs using 
DharmaFECT1 Tranfection Reagent (Dharmacon). Tranfection mix equal to 1:10 of culture medium 
volume was prepared in Opti-MEM™ (Gibco) by mixing siRNA (final 40 nM) with the transfection 
reagent (0.55 μl per 100 μl of the mix, irrespective of number of siRNAs used); the mixture was 
incubated at RT for 10 minutes and added to the cells. The growth medium was replaced after  
24 hours. Sequences of siRNAs used in the study are listed in Table S3. 
 
Cell extracts 
Unless otherwise stated, human and insect cells were lysed by incubating PBS-washed cell pellets 
with 5 PCV (packed-cell volume) of Lysis Buffer (50 mM Na-phosphate pH 7.0, 150 mM NaCl, 10% 
glycerol, 0.1% NP-40, 1 mM TCEP, 0.5 mM EDTA), supplied with protease inhibitors cocktail 
(Roche) and, optionally, 0.1% Benzonase® (Sigma) or PhosSTOP™ (Roche), for 30 minutes on ice 
with intermittent vortexing. Next, lysates were spun down at 17,200 x g for 30 minutes at 4 °C; 
supernatants were collected. If needed, concentrations of the lysates were analysed using Bradford 
assay and normalised.  
 
Western blotting 
For protein analysis by western blotting, samples were boiled in Laemmli sample buffer and 
separated by SDS-PAGE run at 180 V for 1 h or 100 V for 2 h. Proteins were then transferred onto 
nitrocellulose or PVDF membranes at 100 V for 1-2 hours in the cold. Afterwards, membranes were 
blocked in 5% milk-TBST (Tris-buffered saline supplemented with 0.01% Tween®20) solution for 30 
minutes and incubated with primary antibody solution overnight at 4 °C. Then, membranes were 
briefly washed with TBST and incubated with appropriate secondary antibody (1:5000) for 2 hours 
at RT. The membranes were then washed several times with TBST and the signal was developed 
using Clarity™ Western ECL Blotting Substrate (Bio-Rad) or SuperSignal™ West Femto Maximum 
Sensitivity Substrate (Thermo Scientific). 
Primary and secondary antibodies used in this study are listed in Table S4.  
 
DNA fibre analysis 
DNA fibre analysis was carried out following a previously published protocol (Jackson and Pombo, 
1998). Prior to the analysis of DNA fibres, cells were seeded in 12-well plates at a density which 
ensured that the cultures were 70-80% confluent at the day of labelling. Immediately before 
labelling, cells were washed 3 times with pre-warmed PBS (phosphate-buffered saline). Next, cells 
were incubated with DMEM containing 0.04 mM CldU (5-Chloro-2´deoxyuridine, Sigma), followed 
by washing with pre-warmed PBS (3 times, brief). Subsequently, cells were incubated with DMEM 
containing 0.34 mM IdU (5´-Iodo-2´deoxyuridine, Sigma), followed by a 5 hours incubation with 4 
mM hydroxyurea. Afterwards, cells were washed with PBS as previously and harvested by 
trypsinisation. The cells were counted, diluted to 2.5 x105 cells/ml and mixed with unlabelled cells 
at a 1:1 ratio. Then, 3 μl of the cell suspension was spotted onto a glass slide, 7 μl of Fibre Lysis 
buffer was added (200 mM Tris-Cl pH 7.4, 50 mM EDTA, 0.5% SDS in sterilised water; filtered) and 
the drop was pipetted up and down 5 times, avoiding drop expansion. Slides were incubated at RT 
for 9 minutes and tilted manually at an angle that would allow the drop to slide smoothly to the 
bottom in 10-15 seconds. Next, the slides were air-dried and fixed overnight in a 3:1 mix of 
methanol and glacial acetic acid. The slides were then washed in PBS (2 x 3 min) and DNA was 
denatured in 2.5 M HCl for 1 hour at RT. The slides were washed in PBS (2 x 3 min) and 
subsequently blocked in freshly prepared Blocking Buffer (1x PBS containing 2% Bovine serum 
albumin and 0.1% Tween® 20; filtered) for 40 minutes at RT. Next, 60 μl of the primary antibody 
mix was added on top of the slide and the slide was covered with a cover slip. The slides were 
incubated at RT for 2.5 hours, before cover slips were carefully removed and the slides were 
washed with PBST (1x PBS containing 0.2% Tween® 20; 5 x 3 min). Incubation with the secondary 
antibody mix and washing was done in the same way as for the primary antibody. Subsequently, 
the slides were air-dried in the dark, mounted with 20 μl of ProLong™ Gold Antifade Mountant 
(Invitrogen), and stored at 4 °C. DNA fibres were visualised (60X objective, IX81, Olympus coupled 
to a CCD camera, Hammatsu) and scored using ImageJ.  
For each biological replicate 100-200 replication tracts were scored, the IdU/CldU ratio was 
calculated for each fork, and a Kruskal-Wallis test was employed for statistical analysis within a 
single experiment. To correct for variations in between experiments, we then normalised the 
median IdU/CldU ratio for each sample to the experimental control (siControl) within an individual 
experiment. This value serves to describe the ‘extent of fork degradation’ for a single biological 
replicate for a given sample.  
For the final analysis, the mean extent of fork degradation was determined by dividing the sum of 
the normalised median IdU/CldU ratios of each sample by the number of biological replicates (3 or 
more). While not standard in the field we decided to do this because in our view it is necessary to 
collect data from several independently conducted experiments and perform statistical analysis on 
biological replicates (individual experiments), rather than technical replicates (individual replication 
forks within the same sample) to assess a biological phenotype and its significance. The final 
statistical analysis was done using one-way ANOVA with Sidak's correction for multiple 
comparisons. All raw and normalised median values, the number of replication tracks scored and all 
p-values are reported in Table S1. 
 
Inhibitors treatment 
For the analysis of replication fork degradation with DNA fibres, mirin (Sigma Aldrich) and PFM01 
(Sigma Aldrich) were added to the cells 30 minutes prior the pulse-labelling with thymidine 
analogues to final concentrations of 50 and 10 μM, respectively, and kept throughout the labelling 
and hydroxyurea treatment. The DNA2 inhibitor C5 (Aobious Inc.) was used at a final concentration 
of 20 μM and was added together with hydroxyurea. 
 
RT-PCR 
For WRNIP1 mRNA analysis, total RNA was extracted from U2OS cells using RNeasy Mini Kit 
(Qiagen). Then, cDNA synthesis was done using the High Capacity RNA-to-cDNA Kit (Applied 
Biosystems) according to the manufacturer's protocol, followed by end-point PCR with WRNIP1-
specific primers. 
 
WRNIP1 sequence alignment 
Primary sequence alignment was done using Clustal Omega algorithm, accessed through the 
Uniprot website (www.uniprot.org). Accession numbers of aligned proteins were: Q96S55-2 (H. 
sapiens), Q96S55-1 (H. sapiens), Q91XU0 (M. musculus), Q75JU2 (D. discoideum), P40151 (S. 
cerevisiae), O13984 (S. pombe) and P0AAZ4 (E. coli). 
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